Evidence map›Paper›PMID 35111090›Full record

ArticleFrontiers in psychiatry2021

Intranasal Oxytocin for Stimulant Use Disorder Among Male Veterans Enrolled in an Opioid Treatment Program: A Randomized Controlled Trial.

Christopher S Stauffer, Salem Samson, Alex Hickok, William F Hoffman, Steven L Batki

Open access · goldAbstract read
In one paragraph

Article in Frontiers in psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Christopher S StaufferDepartment of Mental Health, VA Portland Health Care System, Portland, OR, United States.
Salem SamsonSchool of Nursing, Massachusetts General Hospital (MGH) Institute of Health Professions, Boston, MA, United States.
Alex HickokDepartment of Mental Health, VA Portland Health Care System, Portland, OR, United States.
William F HoffmanDepartment of Mental Health, VA Portland Health Care System, Portland, OR, United States.
Steven L BatkiDepartment of Psychiatry and Behavioral Sciences, San Francisco School of Medicine and San Francisco VA Health Care System, University of California, San Francisco, San Francisco, CA, United States.
San Francisco VA Health Care System · USMassachusetts General Hospital · USOregon Health & Science University · USVA Portland Health Care System · US

Funding

CSRD VA IK2 CX001495
6 · The paper itself

Abstract

The increasing prevalence of illicit stimulant use among those in opioid treatment programs poses a significant risk to public health, stimulant users have the lowest rate of retention and poorest outcomes among those in addiction treatment, and current treatment options are limited. Oxytocin administration has shown promise in reducing addiction-related behavior and enhancing salience to social cues. We conducted a randomized, double-blind, placebo-controlled clinical trial of intranasal oxytocin administered twice daily for 6 weeks to male Veterans with stimulant use disorder who were also receiving opioid agonist therapy and counseling (

Indexed as

amphetamine-related disordersmethadoneopiate substitution treatmentopioid-related disordersoxytocinstimulanttreatment adherence and complianceveterans

Identifiers

PMID35111090
PMCPMC8801418
OpenAlexW4206275404

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.